VB0 Stock Overview
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
Viva Biotech Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.18|
|52 Week High||HK$0.68|
|52 Week Low||HK$0.18|
|1 Month Change||-21.37%|
|3 Month Change||-39.07%|
|1 Year Change||-72.54%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-64.14%|
Recent News & Updates
|VB0||DE Life Sciences||DE Market|
Return vs Industry: VB0 underperformed the German Life Sciences industry which returned -41.9% over the past year.
Return vs Market: VB0 underperformed the German Market which returned -25.4% over the past year.
|VB0 Average Weekly Movement||6.8%|
|Life Sciences Industry Average Movement||7.3%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||10.0%|
|10% least volatile stocks in DE Market||2.8%|
Stable Share Price: VB0 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: VB0's weekly volatility (7%) has been stable over the past year.
About the Company
|2008||2,309||Chen Cheney Mao||https://www.vivabiotech.com.cn|
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins.
Viva Biotech Holdings Fundamentals Summary
|VB0 fundamental statistics|
Is VB0 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VB0 income statement (TTM)|
|Cost of Revenue||CN¥1.51b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.058|
|Net Profit Margin||5.09%|
How did VB0 perform over the long term?See historical performance and comparison
Is VB0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VB0?
Other financial metrics that can be useful for relative valuation.
|What is VB0's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does VB0's PE Ratio compare to its peers?
|VB0 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
PSG PharmaSGP Holding
VB0 Viva Biotech Holdings
Price-To-Earnings vs Peers: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the peer average (45.6x).
Price to Earnings Ratio vs Industry
How does VB0's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the European Life Sciences industry average (40.8x)
Price to Earnings Ratio vs Fair Ratio
What is VB0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||23.2x|
|Fair PE Ratio||50.3x|
Price-To-Earnings vs Fair Ratio: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the estimated Fair Price-To-Earnings Ratio (50.3x).
Share Price vs Fair Value
What is the Fair Price of VB0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VB0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VB0's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Viva Biotech Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VB0's forecast earnings growth (61.1% per year) is above the savings rate (-0.01%).
Earnings vs Market: VB0's earnings (61.1% per year) are forecast to grow faster than the German market (9.8% per year).
High Growth Earnings: VB0's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VB0's revenue (32.7% per year) is forecast to grow faster than the German market (3.8% per year).
High Growth Revenue: VB0's revenue (32.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VB0's Return on Equity is forecast to be low in 3 years time (10.9%).
Discover growth companies
How has Viva Biotech Holdings performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VB0 has high quality earnings.
Growing Profit Margin: VB0's current net profit margins (5.1%) are lower than last year (15%).
Past Earnings Growth Analysis
Earnings Trend: VB0's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: VB0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VB0 had negative earnings growth (-51.3%) over the past year, making it difficult to compare to the Life Sciences industry average (26.3%).
Return on Equity
High ROE: VB0's Return on Equity (3%) is considered low.
Discover strong past performing companies
How is Viva Biotech Holdings's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: VB0's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: VB0's short term assets (CN¥2.0B) do not cover its long term liabilities (CN¥3.1B).
Debt to Equity History and Analysis
Debt Level: VB0's net debt to equity ratio (52.6%) is considered high.
Reducing Debt: VB0's debt to equity ratio has increased from 3.7% to 70.7% over the past 5 years.
Debt Coverage: VB0's debt is not well covered by operating cash flow (5.5%).
Interest Coverage: VB0's interest payments on its debt are not well covered by EBIT (1.3x coverage).
Discover healthy companies
What is Viva Biotech Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VB0's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VB0's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VB0's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VB0's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: VB0 is not paying a notable dividend for the German market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VB0 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chen Cheney Mao (60 yo)
Dr. Chen Cheney Mao, Ph D has been Chairman and Chief Executive Officer of Viva Biotech Holdings since July 03, 2018. He Founded Viva Biotech Holdings.Dr. Mao is the Chairman and Executive Director of Viv...
Experienced Management: VB0's management team is considered experienced (4.2 years average tenure).
Experienced Board: VB0's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|13 Sep 22||Buy€2,182,966||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||10,521,208||€0.21|
|05 Sep 22||Buy€27,731||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||126,000||€0.22|
|02 Sep 22||Sell€2,373,961||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||10,354,208||€0.23|
|30 Aug 22||Buy€17,093||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||75,500||€0.23|
|24 Aug 22||Sell€431,883||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||1,858,969||€0.23|
|15 Aug 22||Buy€124,349||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||474,799||€0.26|
|12 Aug 22||Sell€117,729||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||447,799||€0.26|
|11 Aug 22||Buy€294,406||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||1,124,833||€0.26|
|04 Aug 22||Sell€1,632,715||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||6,402,424||€0.26|
|28 Jul 22||Sell€6,183,023||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||22,196,274||€0.28|
|26 Jul 22||Buy€5,310,611||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||18,937,702||€0.28|
|30 May 22||Buy€8,218,182||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||30,003,500||€0.27|
|25 May 22||Sell€8,514,294||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||30,542,994||€0.28|
|24 May 22||Sell€2,985,782||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||10,530,458||€0.28|
|23 May 22||Buy€3,191,018||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||10,375,458||€0.31|
|17 May 22||Sell€191,453||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||706,270||€0.27|
|13 May 22||Buy€594,265||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||2,167,770||€0.27|
|05 May 22||Buy€1,951,942||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||6,764,424||€0.29|
|25 Apr 22||Buy€1,644,225||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||5,689,560||€0.29|
|21 Mar 22||Sell€2,335,206||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||6,649,424||€0.35|
|17 Mar 22||Buy€2,608,560||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||7,868,151||€0.33|
|09 Mar 22||Sell€283,491||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||958,000||€0.30|
|24 Feb 22||Buy€2,014,975||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||5,765,000||€0.35|
|27 Jan 22||Sell€347,277||Mao Investment Trust||Company||811,500||€0.43|
|26 Jan 22||Sell€3,932,950||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||8,508,523||€0.46|
|24 Jan 22||Buy€2,874,623||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||6,009,069||€0.48|
|21 Jan 22||Sell€187,353||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||331,500||€0.57|
|20 Jan 22||Buy€164,033||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||359,000||€0.46|
|12 Jan 22||Buy€674,729||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||1,327,500||€0.51|
|28 Dec 21||Buy€5,247,334||Zhang and Sons Limited||Company||10,000,000||€0.52|
|28 Dec 21||Sell€5,247,714||Chen Cheney Mao||Individual||10,000,000||€0.52|
|23 Dec 21||Sell€6,294||JPMorgan Chase & Co, Private Banking and Investment Banking Investments||Company||12,000||€0.52|
|23 Dec 21||Sell€6,229,697||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||11,877,065||€0.52|
|21 Dec 21||Buy€6,497||JPMorgan Chase & Co, Private Banking and Investment Banking Investments||Company||12,000||€0.54|
|21 Dec 21||Sell€9,845,703||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||18,184,418||€0.54|
|20 Dec 21||Buy€10,465,553||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||19,245,418||€0.54|
|15 Dec 21||Buy€7,674,675||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||13,722,065||€0.56|
|08 Dec 21||Sell€844,187||UBS Asset Management||Company||1,390,000||€0.61|
|07 Dec 21||Sell€7,720,355||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||12,577,565||€0.61|
|30 Nov 21||Sell€6,984,077||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||13,084,418||€0.53|
|26 Nov 21||Buy€9,444,639||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||16,717,254||€0.56|
|24 Nov 21||Sell€10,401,700||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||18,775,039||€0.55|
|23 Nov 21||Buy€11,600,128||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||20,931,807||€0.55|
|17 Nov 21||Buy€12,968,914||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||21,532,213||€0.60|
|12 Nov 21||Sell€6,908,793||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||12,040,064||€0.57|
|11 Nov 21||Buy€6,773,189||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||12,000,564||€0.56|
|05 Nov 21||Sell€13,361,398||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||24,279,517||€0.55|
|03 Nov 21||Buy€6,974,644||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||13,736,000||€0.51|
|03 Nov 21||Sell€8,185,032||Chen Cheney Mao||Individual||15,000,000||€0.55|
|01 Nov 21||Buy€1,051,051||Zhang and Sons Limited||Company||15,000,000||€0.07|
|28 Oct 21||Buy€7,091,583||JPMorgan Chase & Co, Brokerage and Securities Investments||Company||11,043,081||€0.64|
|04 Oct 21||Buy€134,853||Ying Wu||Individual||210,000||€0.64|
|30 Sep 21||Buy€69,137||Ying Wu||Individual||107,500||€0.64|
|29 Sep 21||Buy€124,880||Ying Wu||Individual||200,000||€0.62|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Viva Biotech Holdings's employee growth, exchange listings and data sources
- Name: Viva Biotech Holdings
- Ticker: VB0
- Exchange: DB
- Founded: 2008
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$2.902b
- Listing Market Cap: HK$368.900m
- Shares outstanding: 1.91b
- Website: https://www.vivabiotech.com.cn
Number of Employees
- Viva Biotech Holdings
- No.735, Ziping Road
- Zhoupu Town
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1873||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||May 2019|
|VB0||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 2019|
|VBIZ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/17 00:00|
|End of Day Share Price||2022/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.